Free Access
Med Sci (Paris)
Volume 38, Number 2, Février 2022
Page(s) 177 - 181
Section M/S Revues
Published online 18 February 2022
  1. March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010 ; 25 : 544–551. [CrossRef] [PubMed] [Google Scholar]
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 ; 81 : 19–25. [Google Scholar]
  3. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016 ; 31 : 2841–2855. [CrossRef] [PubMed] [Google Scholar]
  4. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015 ; 149 : R219–R227. [CrossRef] [PubMed] [Google Scholar]
  5. Ollila MM, West S, Keinanen-Kiukaaniemi S, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective population-based cohort study. Hum Reprod 2017 ; 32 : 968. [CrossRef] [PubMed] [Google Scholar]
  6. Marchesan LB, Spritzer PM. ACC/AHA 2017 definition of high blood pressure : implications for women with polycystic ovary syndrome. Fertil Steril 2019 ; 111 : 579–587. [CrossRef] [PubMed] [Google Scholar]
  7. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016 ; 2 : 16057. [CrossRef] [PubMed] [Google Scholar]
  8. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome : a systematic review and meta-analysis. Hum Reprod Update 2014 ; 20 : 748–758. [CrossRef] [PubMed] [Google Scholar]
  9. Charitidou C, Farmakiotis D, Zournatzi V, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine leves, in women with the polycystic ovary syndrome. Atheroscler 2008 ; 196 : 958–965. [CrossRef] [Google Scholar]
  10. Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018 ; 10 : 364–379. [CrossRef] [PubMed] [Google Scholar]
  11. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 ; 97 : 28–38.e25. [CrossRef] [PubMed] [Google Scholar]
  12. World Health Organization. Combined hormonal oral contraception and risk of venous thromboembolism (VTE). Sexual and reproductive health 2018. http : // [Google Scholar]
  13. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives : venous thrombosis. Cochrane Database Syst Rev 2014; 3 : CD010813. [Google Scholar]
  14. Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018 ; 141 : 287–294. [CrossRef] [PubMed] [Google Scholar]
  15. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Meta-Analysis Cochrane Database Syst Rev 2019; 2019 (11). [Google Scholar]
  16. World Health Organization. Medical eligibility criteria for contraceptive use, 5th ed. Geneva : WHO, 2015. [Google Scholar]
  17. Haverinen A, Kangasniemi M, Luiro K, et al. Ethinyl estradiol vs estradiol valerate in combined oral contraceptives - Effect on glucose tolerance : A randomized, controlled clinical trial. Contraception 2021; 103 : 53–9. [CrossRef] [PubMed] [Google Scholar]
  18. Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome : a systematic review and meta-analysis of observational studies. Hum Reprod 2011 ; 26 : 191–201. [CrossRef] [PubMed] [Google Scholar]
  19. Luque-Ramírez M, Nattero-Chávez L. Ortiz Flores AE, Escobar-Morreale HF. Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome : a systematic review and meta-analysis. Hum Reprod Update 2018 ; 24 : 225–241. [CrossRef] [PubMed] [Google Scholar]
  20. Spritzer PM, Motta AB, Sir-Petermann T, Diamanti-Kandarakis E. Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol 2015 ; 40 : 195–212. [PubMed] [Google Scholar]
  21. Mario FM, Graff SK, Spritzer PM. Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS : a cross-sectional study. J Endocrinol Invest 2017 ; 40 : 377–384. [CrossRef] [PubMed] [Google Scholar]
  22. Graff SK, Mario FM, Ziegelmann P, Spritzer PM. Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS : systematic review and meta-analysis. Int J Clin Pract 2016 ; 70 : 450–461. [CrossRef] [PubMed] [Google Scholar]
  23. Zimmermann Y, Eijkemans MJ, Coelingh Benning HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women : a systematic review and meta-analysis. Hum Reprod Update 2014 ; 20 : 76–105. [CrossRef] [PubMed] [Google Scholar]
  24. Eil C, Edelson SK. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab 1984 ; 59 : 51–55. [CrossRef] [PubMed] [Google Scholar]
  25. Maier PS, Mattiello SS, Lages L, Spritzer PM. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities. Gynecol Endocrinol 2012 ; 28 : 606–610. [CrossRef] [PubMed] [Google Scholar]
  26. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. ESE PCOS Special Interest Group. The polycystic ovary syndrome : a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014 ; 171 : P1–29. [CrossRef] [PubMed] [Google Scholar]
  27. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism : a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012 ; 18 : 146–170. [CrossRef] [PubMed] [Google Scholar]
  28. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000 ; 52 : 587–594. [CrossRef] [PubMed] [Google Scholar]
  29. Spritzer PM, Barone CR, Oliveira FB. Hirsutism in Polycystic Ovary Syndrome : Pathophysiology and Management. Curr Pharm Des 2016 ; 22 : 5603–5613. [CrossRef] [PubMed] [Google Scholar]
  30. Savio MC, Fata R, Facchinetti F, Grandi G. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen : a new option for oral contraception. Expert Rev Clin Pharmacol 2020; 13 : 685–94. [CrossRef] [PubMed] [Google Scholar]
  31. Kuttenn F, Rigaud C, Wright F, Mauvais-Jarvis P. Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol. J Clin Endocrinol Metab 1980 ; 51 : 1107–1111. [CrossRef] [PubMed] [Google Scholar]
  32. Mowszowicz I, Wright F, Vincens M, et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem 1984 ; 20 : 757–761. [CrossRef] [PubMed] [Google Scholar]
  33. Graillon T, Boissonneau S, Appay R, et al Meningiomas in patients with long-term exposition to progestins : Characteristics and outcome. Neurochirurgie 2021 : S0028–3770(21)00145–4. [PubMed] [Google Scholar]
  34. Weill A, Nguyen P, Labidi M, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women : cohort study. BMJ 2021; 372 : n37. [CrossRef] [PubMed] [Google Scholar]
  35. Grimes DA, Lopez LM, O’Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev 2013; 11 : CD007541. [Google Scholar]
  36. da Silva AV, de Melo AS, Barboza RP, et al. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects. Reprod Sci 2016 ; 23 : 877–884. [CrossRef] [PubMed] [Google Scholar]
  37. Diamanti-Kandarakis E, Spritzer PM, Sir-Petermann T, Motta AB. Insulin resistance and polycystic ovary syndrome through life. Curr Pharm Des 2012 ; 18 : 5569–5576. [CrossRef] [PubMed] [Google Scholar]
  38. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited : an update on mechanisms and implications. Endocr Rev 2012 ; 33 : 981–1030. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.